Liquidia Corporation
LQDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. With a market capitalization of $3.82B, it sits in mid-cap territory. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Market Cap
$3.82B
Beta
0.61
P/E (TTM)
30.68
P/E (Fwd)
19.50
EPS (TTM)
$1.39
EPS (Fwd)
$2.19
ROE
131.8%
ROA
27.0%
Cash
$284.2M
Total Debt
$182.9M
Free CF
$74.3M
52W Change
87.4%
Annual Financials
Cash vs Debt
Where LQDA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LQDA finished 42.61% below its 150-day moving average ($59.47) and 36.70% below its 200-day moving average ($53.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LQDA overbought or oversold?
At the October 20, 2026 close, LQDA's RSI(14) was 18.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $284.2M in cash comfortably exceeding the $182.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $74.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 131.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 27.0% further supports the picture of efficient asset utilization. Revenue has grown from $15.9M (2022) to $158.3M (2025), reflecting a 894% increase over the period.
The relatively low beta of 0.61 suggests LQDA is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Liquidia Corporation's trajectory.